7-9 September, Amsterdam
P-01 | Multimodal and spatial analysis of tumour-immune microenvironment in steatosis-driven hepatocellular carcinoma | Aldo Prawira | Received |
P-02 | Inhibition of PARP-1 in KRAS-mutated intrahepatic cholangiocarcinoma exerts positive effects and is mediated by CHK1 kinase | Darko Castven | Received |
P-03 | Hypoxia promotes adenosine efflux to establish the immunosuppressive microenvironment in liver cancer | Carmen Wong | Received |
P-04 | Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma | Binghua Li | Received |
P-05 | Integrated genomic analysis refines molecular classifications of hepatocellular carcinoma based on LICA-FR cohort of 529 samples | Long Pan | Received |
P-06 | The senescent secretome drives the re-emergence of the fetal receptor PLVAP on human hepatic endothelium to promote monocyte transmigration. | Shishir Shetty | Received |
P-07 | Inactivation of histone chaperone complex CAF-1 elicits intrinsic anti-cancer immunity through activating the cytosolic DNA and dsRNA sensing pathways in hepatocellular carcinoma | Chun-Ming Wong | Received |
P-08 | Outcome of Targeting ATR in High Replication Stress murine HCC | JING FANG | Received |
P-09 | Genetic and pathologic features of papillary neoplasms of human biliary system of intrahepatic and extrahepatic bile ducts and gallbladder | Young Nyun Park | Received |
P-13 | Financial and Psychological Burden of HCC Surveillance in Patients with Cirrhosis | Amit Singal | Received |
P-14 | Achievement of Cancer and Drug-free Status by Atezolizumab Plus Bevacizumab Followed by Curative Conversion in Patients with TACE-Unsuitable, Intermediate-stage HCC: A Multicenter Proof-of-Concept Study | Masatoshi Kudo | Received |
P-15 | VETC (vessel that encapsulate tumor cluster) EVALUATED IN LIVER BIOPSY PREDICTS ANTI-ANGIOGENIC BENEFIT IN ADVANCED HCC | Luca Di Tommaso | Received |
P-17 | Association with body mass index and risk of hepatocellular carcinoma according to liver disorder status | HEEJAE JUNG | Received |
P-19 | Drug-eluting beads vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: A Randomized Clinical Trial | Jun-Hui Sun | Received |
P-20 | Prospective study of surveillance non-contrast abbreviated MRI for hepatocellular cancer in patients with suboptimal hepatic visualisation on ultrasound | Mathew Vithayathil | Received |
P-22 | Genomic characteristics of hepatocellular carcinoma patients with response to sorafenib | Sun Young Yim | Received |
P-24 | Cytokine levels and circulating DNA in plasma could be used as serological biomarkers of response to immunotherapy in hepatocellular carcinoma | Beatriz Mínguez | Received |
P-25 | Preliminary Safety Results of a Phase 1/2 Open-label Study on an Anti-GPC3 T-cell Engager, SAR444200, in Patients with Advanced Solid Tumors | Asma Kefsi | Received |
P-27 | Constructing and Experimentally Validating a Disulfidptosis-related Ferroptosis Gene-driven Machine Learning Prognostic Risk Model for Liver Cancer | Cong Zhang | Received |
P-28 | Serine utilization and generation of different lipid species influence the response of hepatocellular carcinoma to lipid depletion | Bichitra Paul | Received |
P-31 | B-CATENIN PATHWAY MUTATIONS PREDICT FAVORABLE OUTCOMES AFTER TRANSARTERIAL CHEMOEMBOLIZATION IN UNRESECTABLE HEPATOCELLULAR CARCINOMA | Kelley Weinfurtner | Received |
P-32 | Lipid-Associated TREM2 Macrophages Mediates Immunosuppressive Microenvironment in Liver Metastasis of Colorectal Cancer | Pengxiang Wang | Received |
P-33 | Identification of novel phosphoproteomic biomarkers in patients with advanced hepatocellular carcinoma (HCC) | Federico Pedicona | Received |
P-34 | Evaluation of Src family of tyrosine kinases and their potential as molecular targets in overcoming liver cancer heterogeneity | Loraine Kay Cabral | Received |
P-35 | Inflammation induced IgA upregulates PD-L1 in cancer associated fibroblasts of HCC and attenuates CD8 T cell function | Sung Woo Cho | Received |
P-36 | Nanosecond pulsed electric field ablation of sequential endothelial progenitor cell-directed endothelial inhibitor/suicide fusion gene for the treatment of hepatocellular carcinoma | Li Jing | Received |
P-37 | Combinations of fostrox (MIV-818), a novel nucleotide prodrug, with lenvatinib or sorafenib shows increased efficacy in nonclinical hepatocellular carcinoma (HCC) models in vivo | Fredrik Oberg | Received |
P-38 | Impact of exosomal miR-4669 on tumor cell behavior and immunosuppressive tumor microenvironment in hepatocellular carcinoma | Toshiaki Nakano | Received |
P-39 | New insight in HCC immuno-vascular microenvironment: interplay between tumoral macrophages and VETC | Camilla De Carlo | Received |
P-40 | Functional dissection of immune infiltrate reveals that HCC enriched VETC vascular phenotype is characterized by the presence of exhausted T cells. | Barbara Durante | Received |
P-41 | Poor sorafenib response in hepatocellular carcinoma is mediated by hypoxia-associated 14-3-3 scaffolding proteins with observed alterations in immune micromilieu | Jovana Castven | Received |
P-42 | Synergistic antitumor activity of lenvatinib and lipophilic statins in hepatocellular carcinoma | Hyeyeon Hong | Received |
P-44 | GDF11 reduces aggressive behavior provided by tumor-associated macrophages on HCC-derived cells. | Oscar Alejandro Escobedo Calvario | Received |
P-45 | Effect of Zinc Acexamate treatment in hepatocellular carcinoma in vitro and in vivo models | Beatriz Mínguez | Received |
P-46 | Identification of the epidrivers facilitating hepatocellular carcinoma recurrence | Hyun Goo Woo | Received |
P-47 | Gene regulatory network analysis on snRNAseq revealed key regulators for hepatocellular carcinoma progression | Su Jong Yu | Received |
P-48 | Lenvatinib induced cell death of hepatocellular carcinoma by increasing HIF-a degradation under hypoxic condition | Sung Won Chung | Received |
P-50 | CD73 expression on liver endothelium is promoted by tumour associated stimuli and could contribute to the immunosuppressive microenvironment in hepatocellular carcinoma | Rosemary Faulkes | Received |
P-51 | Fructose promotes chemoresistance through the induction of a metabolic rewiring in liver cancer cells and a KHK-A/p27 non-canonical pathway. | Lisette Chávez Rodríguez | Received |
P-52 | LI-RADS classification of proliferative hepatocellular carcinomas and its implication on prognosis | Subin Heo | Received |
P-54 | The Outcomes of Patients with Hepatocellular Carcinoma and with Child-Turcotte-Pugh Class B | Chia Chu Fu | Received |
P-55 | Prediction of Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients following HBsAg seroclearance | Jonggi Choi | Received |
P-56 | Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC | Federico Piñero | Received |
P-58 | Tumor response-based nomogram for ion of patients with hepatocellular carcinoma benefitting from drug-eluting bead transarterial chemoembolization | Cong Zhang | Received |
P-59 | Effect of chemotherapeutic agents on acute kidney injury in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: doxorubicin versus cisplatin | Won Sohn | Received |
P-60 | Treatment outcomes in patients with advanced fibrolamellar hepatocellular carcinoma: analysis of clinical characteristics and radiomics phenotypes | Leonardo da Fonseca | Received |
P-63 | Implication of patients experience in the liver cancer multidisciplinary approach | Gemma Iserte | Received |
P-65 | Sarcopenia affects the therapeutic efficacy of immunotherapy for advanced Hepatocellular carcinoma. | Takuya Kuwashiro | Received |
P-68 | Consistent efficacy of Hepatic Artery Infusion Chemotherapy irrespective of PD-L1 positivity in unresectable hepatocellular carcinoma | Ji Hoon Kim | Received |
P-69 | Differences in Outcomes Between Screen-Detected and Non-Screen Detected Hepatocellular Carcinoma | Darine Daher | Received |
P-71 | Correlates and Outcomes of CT or MRI-based Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis | Darine Daher | Received |
P-72 | Clinical Performance of GAAD and GALAD Algorithmic Scores for Hepatocellular Carcinoma (HCC) surveillance in Patients with Chronic Hepatitis | Ming-Lung Yu | Received |
P-74 | Discrepancy between the real clinical status of patients with HCC and expectations from HCC surveillance: a single center study | Jiwoong Jang | Received |
P-75 | Peripheral immune markers can detect hepatocellular carcinoma in blood in a Latin American cohort | Andre Boonstra | Received |
P-76 | Evaluation of the Accuracy of Imaging Diagnosis for Hepatocellular Carcinoma in Chronic Hepatitis C Patients without Liver Cirrhosis | Jihyun An | Received |
P-80 | Differentiation of Primary Malignant Vascular Tumors using CT and Gadoxetate-enhanced Liver MRI | So Yeon Kim | Received |
P-81 | Pan-viral serology uncovers distinct virome patterns among hepatocellular carcinoma and control populations | Whitney Do | Received |
P-82 | Role of Tumor Markers in Diagnosing Recurrent Hepatocellular Carcinoma after Curative Resection | Jeong Ah Hwang | Received |
P-83 | Performance of tumor-specific microRNAs as plasma biomarkers of hepatocellular carcinoma in patients with liver cirrhosis | Robin Zenlander | Received |
P-85 | Five-year on-treatment parameters-based model predicts subsequent hepatocellular carcinoma in entecavir/tenofovir-treated patients | Yeonjung Ha | Received |
P-86 | Evaluating performance of aMAP score in predicting hepatocellular carcinoma development over a two-year period in cirrhosis patients | Avisnata Das | Received |
P-89 | Early detection of hepatocellular carcinoma using urinary metabolomic biomarkers in an Australian Aboriginal population. | Paula Binks | Received |
P-90 | Physician and patient survey of practices and perspectives in the surveillance and diagnosis of hepatocellular carcinoma (HCC) in Asia: unmet needs in the real world | Iain Murdoch | Received |
P-91 | IMbrave050: Phase 3 study of adjuvant atezolizumab bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | Elyse Viana | Received |
P-92 | Risk of Gastrointestinal Bleeding in Patients Receiving AtezolizumabBevacizumab Treatment for Hepatocellular Carcinoma | Jonggi Choi | Received |
P-93 | Real-world (RW) systemic treatment patterns in US patients (pts) with hepatocellular carcinoma (HCC): 20202022 | Rego Team | Received |
P-94 | Systemic Treatment in Child Pugh B Patients with Hepatocellular Carcinoma | Kevin Mok | Received |
P-95 | Semaglutide, but not lanifibranor, promotes tumor regression in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH with advanced fibrosis and HCC | Denise Oró | Received |
P-96 | Metabolic dysfunction associated fatty liver disease and the risk of hepatocellular carcinoma | BYEONGGEUN SONG | Received |
P-97 | Randomized phase II trial to assess safety and efficacy of regorafenib in patients with advanced hepatocellular carcinoma who were not included in the RESORCE trial: REGAIN trial | Keisuke Koroki | Received |
P-98 | A Study on the Sequence of Systemic Treatment in Hepatocellular Carcinoma | Kevin Mok | Received |
P-99 | Macrotrabecular-Massive pattern is associated with aggressive factors, but it is not an independent predictor of tumor recurrence and overall survival in patients with hepatocelular carcinoma treated with liver resection | Ezequiel Mauro | Received |
P-100 | Validation of Baveno-VII criteria for clinically significant portal hypertension in patients with compensated advanced chronic liver disease | BYEONGGEUN SONG | Received |
P-101 | The predictive value of liver volume on hepatic decompensation and the long-term effects of stereotactic body radiation therapy on hepatic decompensation | JINHONG JUNG | Received |
P-102 | A prospective study to evaluate the safety and efficacy of lenvatinib in patients with advanced hepatocellular carcinoma to maximise its potential in current practice | Kazufumi Kobayashi | Received |
P-104 | Real-time US-CT/MR Fusion Imaging-guided Anatomical Ablation for Small Hepatocellular Carcinomas Using Multiple Applicators: A Preliminary Study | Jae Hyun Kim | Received |
P-105 | Glypican-3-targeted radiopharmaceutical therapy for hepatocellular carcinoma: Preclinical characterization of a novel peptide radioligand | Fanching Lin | Received |
P-107 | A Multicenter Propensity Score Matching Analysis of the Clinical Outcome of Atezolizumab/Bevacizumab and Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Comparative study | Hee Sun Cho | Received |
P-108 | Single arm study to evaluate the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma patients in Japanese real-world practice; focusing on the complement of the REACH-2 study: R-evolution trial | Kazufumi Kobayashi | Received |
P-109 | Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment other than sorafenib or due to sorafenib intolerance | Marco Sanduzzi Zamparelli | Received |
P-110 | Lung-specific response to atezolizumab plus bevacizumab is associated with overall survival in patients with lung metastasis from hepatocellular carcinoma | Ju Hyun Shim | Received |
P-111 | Clinical Outcomes of Stereotactic Body Radiation Therapy Alone versus Stereotactic Body Radiation Therapy after Incomplete Transarterial Chemoembolization for a Single Small (= 5 cm) Recurrent Hepatocellular Carcinoma | JINHONG JUNG | Received |
P-112 | Metastasectomy versus stereotactic body radiation therapy for pulmonary oligometastasis from hepatocellular carcinoma: a propensity score-weighted analysis | Sang Min Yoon | Received |
P-113 | Palliative care in patients with BCLC-D hepatocellular carcinoma not indicated for liver transplantation: results of a survey among Italian hepatologists and palliative care physicians. | Lorenzo Canova | Received |
P-114 | Portal-hypertension parameters are associated with transplantation free survival and ascites occurrence in patients with hepatocellular carcinoma treated by external radiotherapy | Héloïse Giudicelli | Received |
P-115 | Significance of autoantibody assay in patients receiving atezolizumab and bevacizumab combination therapy for unresectable hepatocellular carcinoma | Hitomi Takada | Received |
P-117 | Value based Healthcare: Patient perception of the liver cancer Advanced Practice Nurse care at the Barcelona Clinic Liver Cancer | Neus Llarch | Received |
P-118 | Salvage Hepatectomy for Recurrent Hepatocellular Carcinoma after Radiofrequency Ablation | Jai Young Cho | Received |
P-119 | A real-world comparative analysis of atezolizumab plus bevacizumab and transarterial chemoembolization plus radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombosis | Jong Young Choi | Received |
P-123 | Liver-directed combined radiotherapy for downstaging of over the Milan advanced hepatocellular carcinoma converting to liver transplantation | jinsil seong | Received |
P-124 | Comparative Analysis of combination therapy (Atezolizumab bevacizumab) and hepatic artery infusion chemotherapy in Unresectable Hepatocellular carcinoma: A multi-center study | Ji Hoon Kim | Received |
P-126 | The efficacy and safety of Toripalimab combined with Sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study | Xin-Rong Yang | Received |
P-127 | Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma | Judith Land | Received |
P-128 | Association of alcohol consumption with liver cancer and all-cause mortality in chronic hepatitis B patients without cirrhosis | Beom Kyung Kim | Received |
P-129 | FGFR2 Pathway Activation Beyond The Alteration of FGFR Receptor in Intrahepatic Cholangiocarcinoma | Chiara Deiana | Received |
P-130 | Differential risk of hepatic events during immune checkpoint inhibitor treatment between hepatocellular carcinoma and other malignancies | Yi-Hsiang Huang | Received |
P-131 | The expression of Aurora kinase A in hepatocarcinogenesis and its role in Programmed DeathLigand 1 regulation | Luca Grisetti | Received |
P-132 | Weakly supervised primary liver cancer classification from routine tumour biopsy: a proof of concept | Aurélie Beaufrère | Received |
7-9 September, Amsterdam
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|